Study results from School of Medicine, Department of Gastroenterology broaden understanding of gastric cancer risk factors
2007 NOV 19 -- Researchers detail in 'Multi-drug resistance 1 polymorphism is associated with reduced risk of gastric cancer in the Japanese population,' new data in gastric cancer. According to recent research from Japan, "Host genetic factors play a key role in gastric carcinogenesis, but the mechanism has not been clarified. The multi-drug resistance 1 (MDR1) gene mediates the expression of P-glycoprotein, which has a role in active transport of various substrates, including xenobiotics, and thus has a protective function in various tissues and organs like gastrointestinal epithelial cells." "C3435T polymorphism in exon 26 of the MDR1 gene influences P-glycoprotein expression and activity in the gastrointestinal tract. We investigated the influences of MDR1 gene polymorphism on the risk of gastric cancer The study was performed on 157 patients with gastric cancer (GC) and 104 patients without GC as the control group. C3435T polymorphism of MDR1 was investigated by PCR-RFLP in all of the patients The MDR1 3435 TT genotype showed a significantly higher frequency in controls than in GC patients (OR=0.43; 95% CI=0.23-0.79). There were no significant differences of the CT and CC genotype frequencies between GC patients and controls," wrote T. Tahara and colleagues, School of Medicine, Department of Gastroenterology. The researchers concluded: "We also found that the 3435TT genotype of MDR1 was associated with a lower risk of non-cardiac cancer (OR=0.42; 95% CI=0.23-0.79), middle-third cancer (OR=0.36; 95% CI=0.17-0.77), advanced cancer (OR=0.31; 95% CI=0.13-0.73), venous invasion (OR=0.30; 95% CI=0.10-0.91), and lymph node metastasis (OR=0.28; 95% CI=0.13-0.65) Our data suggest that 3435T/T polymorphism of MDR1 is associated with a reduced risk of gastric cancer in the Japanese population." Tahara and colleagues published their study in the Journal of Gastroenterology and Hepatology (Multi-drug resistance 1 polymorphism is associated with reduced risk of gastric cancer in the Japanese population. Journal of Gastroenterology and Hepatology, 2007;22(10):1678-82). For additional information, contact T. Tahara, School of Medicine, Dept. of Gastroenterology, Toyoake, Aichi, Japan. Publisher contact information for the Journal of Gastroenterology and Hepatology is: Blackwell Publishing Asia, 54 University St., PO Box 378, Carlton, Victoria 3053, Australia. Keywords: Japan, Gastric Cancer Risk Factors, Clinical Trial Research, Drug Development, Drug Resistance, Gastric Cancer, Gastric Carcinoma, Gastroenterology, Hepatology, Oncology, Therapy, Treatment. This article was prepared by Anti-Infectives Week editors from staff and other reports. Copyright 2007, Anti-Infectives Week via NewsRx.com.
|
